The authors showed that NFκB silencing increased anti-apoptotic STEAP2 expression, as well as inhibited p53 and MDM2 expression in TNF-α-treated, STEAP2-overexpressing DU145 cells, suggesting inhibition of NFκB for prostate cancer prevention in specific patients (Gonen-Korkmaz et al., 2014). Here, NFKB1 is linked to prostate carcinoma.